April 1st 2025
Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Expert Perspectives in the Recognition and Management of Postpartum Depression
View More
Southern California Psychiatry Conference
July 11-12, 2025
Register Now!
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
View More
PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia
View More
Southern Florida Psychiatry Conference
November 21-22, 2025
Register Now!
Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?
View More
Optimizing Care for Patients With Tardive Dyskinesia
View More
Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
View More
Brief Screening Tools Can Improve Patient Care
November 29th 2012Medical colleagues routinely monitor patients with sphygmomanometers, peak flow meters, and glucometers. Similarly, psychiatrists can and should incorporate the use of screening tools to help with diagnosis and treatment management.
Read More
You Can’t Turn a Sow’s Ear Into a Silk Purse
November 14th 2012The DSM-5 leadership is trying to put a brave face on its badly failed first stage of field testing and has offered no excuse or explanation for canceling its second and most crucial quality control stage. This field testing fiasco erases whatever was left of the credibility of DSM-5 and APA.
Read More
Update on the Treatment of Bipolar Depression
November 6th 2012There are many rapidly effective treatments for mania in bipolar disorder. However, there are relatively few options for bipolar depression, and none that are rapidly effective-even though bipolar depression constitutes between 20% to 50% of all depressive disorders.
Listen
Are Psychiatric Disorders Inflammatory-Based Conditions?
A plethora of studies support the hypothesis that inflammation plays a role in the pathophysiology of major psychiatric disorders.
Read More
Irreversible Monoamine Oxidase Inhibitors Revisited
October 8th 2012Given the likelihood that insufficient numbers of patients will be available for a randomized controlled trial of MAOIs in refractory depression or atypical depression, we must still rely on consensus guidelines and expert opinion.
Read More
Psychiatric Disorders Associated With Suicide
September 12th 2012Suicide involves a complex array of psychological, biological, social, and cultural factors, and it is particularly likely to occur during periods of individual, family, and socioeconomic crises associated with loss and shame. What 3 psychiatric disorders are most often associated with suicide?
Read More
Coming Along With the DSM-5: Hybrid Models of Psychiatric Diagnosis
September 12th 2012Do not be surprised if you hear more about hybrid models of psychiatric diagnoses included in DSM-5. The categorical and dimensional model approaches are 2 sides of the same coin as you look at the same patient from 2 different angles.
Read More
Effective Personalized Strategies for Treating Bipolar Disorder
August 2nd 2012Effective personalized treatment recognizes bipolar disorder as a biopsychosocial disorder, but mood-stabilizing medications are the backbone of treatment. These medications fall into 3 categories: lithium, antikindling/antiepileptic agents, and second-generation antipsychotics.
Read More
Personalized Biological Testing in Psychiatry: Inevitable Reality or Impossible Dream?
July 19th 2012Our current diagnostic system is based more on subjective clinical judgments and less biological psychiatry. There is not one way to develop symptoms of schizophrenia or bipolar disorder or autistim or OCD.
Read More
Confounding Factors in TRD (Part 1): The Role of Subtyping and Bipolarity
July 19th 2012The current system of payment for mental health care in the US can lead, or even incentivize, clinicians to focus on and code for Axis I disorders and their more readily reimbursed psychopharmacological treatment approaches.
Read More
Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants
July 14th 2012There is rapidly escalating interest in drugs that target the glutamatergic neurotransmitter system, especially NMDA receptor modulators. The hope is that they will fill the large unmet need for rapid-acting antidepressant medications with efficacy in treatment-resistant depression.
Read More
The Duty to Protect: When Has It Been Discharged?
July 2nd 2012The California Supreme Court’s decision in the Tarasoff case over 30 years ago has become a standard part of mental health practice. This case influenced the legal requirements governing therapists’ duty to protect third parties in nearly every state in the US.
Read More
How to End a Psychiatric Epidemic: The Redemption of Psychiatry
June 12th 2012In light of our problems and uncertainties about the state of current psychiatry, or perhaps because of them, what might describe good psychiatry? Following are some suggestions for what we, as psychiatrists, can do.
Read More
Does Evidence-Based Medicine Discourage Richer Assessment of Psychopathology and Treatment?
April 5th 2012The paradigm for modern psychiatry is evidence-based medicine (EBM)-it represents proven treatments for defined diagnoses. But there are major problems with this position, starting with the fact that while they are superior to placebo, evidence-based treatments too often are ineffective.
Read More